Osteoporosis
Annals of Long-Term Care on the Web is a comprehensive resource for clinical information on geriatric medicine and long-term care as well as Osteoporosis. We hope the articles below provide timely information for your practice.
Impact and Pathogenesis of Osteoporosis
It can result pathogenetically from inadequate peak bone mass, excessive bone resorption or impaired bone formation, and be influenced by genetic, hormonal, and environmental factors. The trabecular bone is much more sensitive to metabolic influences; therefore, conditions that produce rapid bone loss tend to affect trabecular bone more quickly than cortical bone. New bone formation exceeds bone resorption during childhood and early adulthood, leading to a net increase in the bone mass.
Osteoporosis in the Aging Male
Risedronate is approved by the FDA for the treatment of glucocorticoid-induced male osteoporosis and is currently being evaluated for the treatment of idiopathic and hypogonadal osteoporosis in men. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers.
Osteoporosis and Aging: Etiology and Current Diagnostic Strategies
Osteoporosis is a disease characterized by low bone mass and microarchitectural deterioration of bone tissue leading to increased bone fragility and fracture risk.1 The new WHO consensus definition reflects the importance of bone mass measurement in the diagnosis of osteoporosis and implies that the occurrence of fractures is not essential to the diagnosis. Bone Histomorphometry Bone histomorphometry assesses the quality of bone, which is independent of bone mass. Urine markers of bone ...
A Multidisciplinary Approach to Managing Osteoporosis
The National Osteoporosis Foundation recommends bone density screening in all postmenopausal women with a recent fracture or with any other risk factor for osteoporosis. Medications to Treat and Prevent Osteoporosis Pharmacists can provide a medication review for individuals who may take drugs that predispose to osteoporosis or falls (Tables II, III). Lifestyle Changes Lifestyle changes can help prevent osteoporosis fractures by preventing development of osteoporosis or preventing falls ...
Osteoporosis in Very Elderly Nursing Home Patients
Osteoporosis in Very Elderly Nursing Home Patients Osteoporosis in Very Elderly Nursing Home Patients Todd H. Goldberg, MD, CMD, FACP, Maria H. Restrepo, MD, and Huyan D. Tran, MD Objective: To describe the prevalence of osteoporosis in frail elderly nursing home patients who are at the highest risk of falls and fractures. Conclusions: This study, although small, demonstrates that most frail women in the nursing home have osteoporosis, usually severe, and may benefit from more aggressive ...
Reducing Hip Fracture Risk in Patients Confined to Long-Term Care Facilities: A Review of Clinical Data
Reducing Hip Fracture Risk in Patients Confined to Long-Term Care Facilities: A Review of Clinical Data Reducing Hip Fracture Risk in Patients Confined to Long-Term Care Facilities: A Review of Clinical Data Murray J. Favus, MD Hip fracture is a debilitating complication of osteoporosis and is a significant source of health care resource utilization among patients confined to long-term care facilities. In the long-term care facility, treatment with alendronate may reduce substantially the ...
Management of Osteoporosis in the Nursing Home Setting
Drug Treatment Options The National Osteoporosis Foundation recommends therapy for osteoporosis be initiated to reduce fracture risk in women with BMD T-scores below -2 SD in the absence of risk factors, and in women with BMD T-scores below -1.5 SD if other risk factors are present. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Randomized trial of ...
Innovative Treatment of Osteoporosis
The bones that fracture in osteoporosis depend predominantly on trabecular bone for structural support. Risk factors can affect peak bone mass, postmenopausal bone loss, and age-related bone loss and include several multifactorial components. By conserving bone mass, estrogen therapy reduces the risk of osteoporosis-related fractures and results in an approximately 40% to 75% reduction of vertebral fractures and a 25% decrease in nonvertebral fractures with five years of use.
Pharmacologic Management of Osteoporosis: Current Trends and Future Prospects
Hormone Replacement Therapy Because hormonal deficiencies result in significant bone loss, a discussion of the pharmacologic management of osteoporosis should begin with the available hormone replacement therapies for osteoporosis, including the administration of estrogen, estrogen analogues, and androgens. Conversely, estrogen replacement therapy (ERT) suppresses bone resorption and prevents bone loss by suppressing cytokine activation, thereby slowing the remodeling cycle.3 The loss of ...
Osteoporosis: A Neglected but Treatable Disease
It can result pathogenetically from inadequate peak bone mass, excessive bone resorption or impaired bone formation, and be influenced by genetic, hormonal, and environmental factors. The trabecular bone is much more sensitive to metabolic influences; therefore, conditions that produce rapid bone loss tend to affect trabecular bone more quickly than cortical bone. New bone formation exceeds bone resorption during childhood and early adulthood, leading to a net increase in the bone mass.
Risedronate is approved by the FDA for the treatment of glucocorticoid-induced male osteoporosis and is currently being evaluated for the treatment of idiopathic and hypogonadal osteoporosis in men. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers.
Osteoporosis is a disease characterized by low bone mass and microarchitectural deterioration of bone tissue leading to increased bone fragility and fracture risk.1 The new WHO consensus definition reflects the importance of bone mass measurement in the diagnosis of osteoporosis and implies that the occurrence of fractures is not essential to the diagnosis. Bone Histomorphometry Bone histomorphometry assesses the quality of bone, which is independent of bone mass. Urine markers of bone ...
The National Osteoporosis Foundation recommends bone density screening in all postmenopausal women with a recent fracture or with any other risk factor for osteoporosis. Medications to Treat and Prevent Osteoporosis Pharmacists can provide a medication review for individuals who may take drugs that predispose to osteoporosis or falls (Tables II, III). Lifestyle Changes Lifestyle changes can help prevent osteoporosis fractures by preventing development of osteoporosis or preventing falls ...
Osteoporosis in Very Elderly Nursing Home Patients Osteoporosis in Very Elderly Nursing Home Patients Todd H. Goldberg, MD, CMD, FACP, Maria H. Restrepo, MD, and Huyan D. Tran, MD Objective: To describe the prevalence of osteoporosis in frail elderly nursing home patients who are at the highest risk of falls and fractures. Conclusions: This study, although small, demonstrates that most frail women in the nursing home have osteoporosis, usually severe, and may benefit from more aggressive ...
Reducing Hip Fracture Risk in Patients Confined to Long-Term Care Facilities: A Review of Clinical Data Reducing Hip Fracture Risk in Patients Confined to Long-Term Care Facilities: A Review of Clinical Data Murray J. Favus, MD Hip fracture is a debilitating complication of osteoporosis and is a significant source of health care resource utilization among patients confined to long-term care facilities. In the long-term care facility, treatment with alendronate may reduce substantially the ...
Drug Treatment Options The National Osteoporosis Foundation recommends therapy for osteoporosis be initiated to reduce fracture risk in women with BMD T-scores below -2 SD in the absence of risk factors, and in women with BMD T-scores below -1.5 SD if other risk factors are present. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study. Randomized trial of ...
The bones that fracture in osteoporosis depend predominantly on trabecular bone for structural support. Risk factors can affect peak bone mass, postmenopausal bone loss, and age-related bone loss and include several multifactorial components. By conserving bone mass, estrogen therapy reduces the risk of osteoporosis-related fractures and results in an approximately 40% to 75% reduction of vertebral fractures and a 25% decrease in nonvertebral fractures with five years of use.
Hormone Replacement Therapy Because hormonal deficiencies result in significant bone loss, a discussion of the pharmacologic management of osteoporosis should begin with the available hormone replacement therapies for osteoporosis, including the administration of estrogen, estrogen analogues, and androgens. Conversely, estrogen replacement therapy (ERT) suppresses bone resorption and prevents bone loss by suppressing cytokine activation, thereby slowing the remodeling cycle.3 The loss of ...